Savara Inc financial data

Symbol
SVRA on Nasdaq
Industry
Pharmaceutical Preparations
Location
6836 Bee Cave Road, Building 3, Suite 201, Austin, TX
State of incorporation
DE
Fiscal year end
December 31
Former names
Mast Therapeutics, Inc. (to 4/25/2017), ADVENTRX PHARMACEUTICALS INC (to 3/1/2013), BIOKEYS PHARMACEUTICALS INC (to 5/15/2003)
Latest financial report
10-K - Q4 2024 - Mar 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.45K % -21.9%
Debt-to-equity 26.1 % -9.11%
Return On Equity 18.5K % +93.9%
Return On Assets -51.2 % -42.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 173M shares +25%
Common Stock, Shares, Outstanding 172M shares +24.8%
Entity Public Float 544M USD +32.6%
Common Stock, Value, Issued 173K USD +23.6%
Weighted Average Number of Shares Outstanding, Basic 198M shares +20%
Weighted Average Number of Shares Outstanding, Diluted 198M shares +20%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 25M USD +59.8%
Operating Income (Loss) -103M USD -72%
Net Income (Loss) Attributable to Parent -95.9M USD -75.3%
Earnings Per Share, Basic -0.48 USD/shares -45.5%
Earnings Per Share, Diluted -0.48 USD/shares -45.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 15.1M USD -43.1%
Assets, Current 202M USD +21.8%
Property, Plant and Equipment, Net 165K USD -38.9%
Operating Lease, Right-of-Use Asset 200K USD -50%
Other Assets, Noncurrent 242K USD -37.5%
Assets 213M USD +19.9%
Accounts Payable, Current 4.55M USD +29.7%
Employee-related Liabilities, Current 5.02M USD +24%
Accrued Liabilities, Current 10.2M USD +43.5%
Liabilities, Current 14.7M USD +38.9%
Operating Lease, Liability, Noncurrent 100K USD -50%
Other Liabilities, Noncurrent 87K USD -64.8%
Liabilities 41.4M USD +11.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -750K USD -177%
Retained Earnings (Accumulated Deficit) -489M USD -24.4%
Stockholders' Equity Attributable to Parent 171M USD +22.1%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -750K USD -177%
Liabilities and Equity 213M USD +19.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -20.6M USD -71.7%
Net Cash Provided by (Used in) Financing Activities 49K USD
Net Cash Provided by (Used in) Investing Activities 10.8M USD
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 172M shares +24.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -9.8M USD +45.9%
Interest Paid, Excluding Capitalized Interest, Operating Activities 536K USD +15.5%
Deferred Tax Assets, Valuation Allowance 107M USD +45.3%
Deferred Tax Assets, Gross 108M USD +44.6%
Operating Lease, Liability 230K USD -33.1%
Payments to Acquire Property, Plant, and Equipment 10K USD +150%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -96.4M USD -77.3%
Lessee, Operating Lease, Liability, to be Paid 247K USD -36.7%
Property, Plant and Equipment, Gross 2.33M USD +1.97%
Operating Lease, Liability, Current 200K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Two 87K USD -45.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 160K USD +11.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 17K USD -63%
Lessee, Operating Lease, Liability, to be Paid, Year Three 87K USD
Deferred Tax Assets, Operating Loss Carryforwards 58.4M USD +30.5%
Preferred Stock, Shares Authorized 1M shares 0%
Share-based Payment Arrangement, Expense 9.86M USD +136%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%